Use only the diluent and equipment supplied or specified by your clinical team do not substitute an alternative diluent
Tirzepatide: A Direct Comparison No large head-to-head randomized controlled trial comparing semaglutide 2.4 mg (Wegovy) to tirzepatide 15 mg (Zepbound) for weight loss has been published as of early 2025, so cross-trial comparisons carry significant limitations
Diabetes Care 30:19791987 Ahren B, Pacini G, Foley JE, Schweizer A (2005) Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
TRIUMPH-1 (80 Weeks) The pivotal TRIUMPH-1 obesity trial (2,339 adults, no diabetes), presented at ADA 2026, extended the treatment window to 80 weeks and produced the largest pivotal weight-loss readout to date: Among the 12 mg group, 45.3% lost at least 30% of their body weight and 65.3% ended the trial with a BMI below 30